Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $159.00 at SVB Leerink

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) had its target price upped by equities researchers at SVB Leerink from $138.00 to $159.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. SVB Leerink’s price target suggests a potential downside of 33.15% from the company’s previous close.

ALNY has been the subject of a number of other research reports. Evercore ISI increased their target price on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research report on Tuesday. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an “equal weight” rating in a report on Tuesday. Royal Bank of Canada raised their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Barclays raised their price target on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an “overweight” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $236.70.

Read Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Stock Up 6.7 %

NASDAQ:ALNY traded up $14.94 during trading hours on Tuesday, reaching $237.84. 1,899,892 shares of the company’s stock were exchanged, compared to its average volume of 806,057. The company has a market capitalization of $30.08 billion, a P/E ratio of -88.75 and a beta of 0.30. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $238.99. The business’s 50-day simple moving average is $151.99 and its two-hundred day simple moving average is $162.59.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. The firm’s revenue was up 54.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.40) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -3.74 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $227,000. Envestnet Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 30.4% in the third quarter. Envestnet Asset Management Inc. now owns 24,570 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 5,727 shares in the last quarter. Hsbc Holdings PLC increased its stake in Alnylam Pharmaceuticals by 14.7% in the third quarter. Hsbc Holdings PLC now owns 35,185 shares of the biopharmaceutical company’s stock valued at $6,230,000 after purchasing an additional 4,508 shares in the last quarter. Acadian Asset Management LLC increased its stake in Alnylam Pharmaceuticals by 52.4% in the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 311 shares in the last quarter. Finally, Northern Trust Corp increased its stake in Alnylam Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 797,700 shares of the biopharmaceutical company’s stock valued at $141,273,000 after purchasing an additional 25,230 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Articles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.